Valuation: Ocugen, Inc.

Market Cap 471M 404M 377M 346M 649M 45.1B 662M 4.47B 1.74B 22.6B 1.77B 1.73B 74.83B P/E 2026 *
-5.35x
P/E 2027 * -4.96x
Enterprise Value 471M 404M 377M 346M 649M 45.1B 662M 4.47B 1.74B 22.6B 1.77B 1.73B 74.83B EV / Sales 2026 *
99.4x
EV / Sales 2027 * 189x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day-6.08%
1 week+2.96%
Current month+13.01%
1 month+4.51%
3 months+2.21%
6 months-13.12%
Current year+2.96%
1 week 1.32
Extreme 1.32
1.49
1 month 1.17
Extreme 1.17
1.49
Current year 1.16
Extreme 1.16
2.72
1 year 1
Extreme 1
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 2019-09-26
Director of Finance/CFO - 2026-02-08
Chief Operating Officer - 2026-02-28
Director TitleAgeSince
Chairman 62 2019-09-26
Director/Board Member 59 2013-08-31
Director/Board Member 59 2019-08-31
Date Insider Type Main position Quantity % Market Cap.
4/1/26 Fiscal year

Director

388,268 0.1184%
1/2/26 Free

Chief Executive Officer

6,246,402 2.0000%
1/2/26 Free

Controller/Auditor

518,250 0.1659%
Change 5-day change 1-year change 3-year change Capi.($)
-6.08%+2.96%+37.62%+214.55% 502M
+1.14%+2.27%+2.38%+24.14% 50.5B
-1.36%+4.82%+485.55%+614.84% 46.01B
-2.04%+3.69%+19.34%+91.23% 42.85B
+2.72%+6.02%+33.33%+19.66% 41.03B
0.00%-3.91%+18.49%+47.98% 32.02B
-1.85%+3.48% - - 17.05B
+0.72%+5.27%+31.55%+145.37% 16.98B
+3.06%+3.88%+5.81%+35.00% 14.3B
+0.50%+3.62%+82.64%+46.53% 13.84B
Average -0.32%+2.92%+79.63%+137.70% 27.51B
Weighted average by Cap. +0.17%+2.75%+104.75%+153.00%

Financials

2026 *2027 *
Net sales 4.74M 4.06M 3.79M 3.47M 6.53M 454M 6.66M 44.92M 17.51M 227M 17.8M 17.41M 753M 2.5M 2.14M 2M 1.83M 3.44M 239M 3.51M 23.69M 9.24M 120M 9.39M 9.18M 397M
Net income -88.53M -75.8M -70.72M -64.89M -122M -8.47B -124M -839M -327M -4.25B -332M -325M -14.05B -97.94M -83.85M -78.24M -71.79M -135M -9.37B -138M -928M -362M -4.7B -368M -360M -15.55B
Net Debt - -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
26-08-20 US$1.390 -6.08% 3,955,534
26-08-19 US$1.480 +10.45% 6,882,661
26-08-18 US$1.340 -2.55% 2,527,228
26-08-17 US$1.375 +1.85% 2,501,078
26-08-14 US$1.350 0.00% 2,978,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.390USD
Average target price
12.17USD
Spread / Average Target
+775.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCGN Stock